Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.
Entinostat inhibits class I HDAC1 and HDAC3 with IC<sub>50</sub> of 0.51 üM and 1.7 üM, respectively.
Syndax pharmaceuticals currently holds the rights to entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.
It has also been investigated as a potential male contraceptive drug.